Multiple BITT antibodies showed strong antagonist activity in B-cell proliferation assays. Two BITT CD40 antagonists were selected for testing in a humanized NSG Mouse Model of graft verse host disease. The BITT CD40R antagonists were compared to isotype control and a known IgG1 CD40R antagonist....
IL-1RA (Interleukin-1 receptor antagonist)peptide 白介素-1受体拮抗剂抗原进口/国产 规格: 0.5mg 白细胞分化抗原配体40(CD40/TNFRSF5)ELISA检测试剂盒 直销细胞毒1蛋白酶(HIV-1 PROTEASE)活性荧光淬灭法定量检测试剂盒 进口/国产 规格:20次 组织毒1蛋白酶(HIV-1 PROTEASE)活性荧光淬灭法定量检测试剂盒 进...
Anti-Human CD40 Monoclonal Antibody(Lucatumumab);卢卡木单抗,仅用于工业应用或科学研究,不可用于人类或动物的临床诊断或治疗,非药用. Lucatumumab (HCD122) is a fully human anti-CD40 antagonist monoclonal antibody, whic
Boston Immune Technologies and Therapeutics, Inc., a privately held developer of novel tumor necrosis factor superfamily receptor antagonist antibodies, announced updates on the company’s DOMab™ platform. BOSTON--(BUSINESS WIRE)-- Boston Immune Technologies and Therapeutics, Inc. (BITT), a ...
. A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants with Relapsing Multiple Sclerosis. (7 June 2021). Identifier: NCT04879628. Available online: https://clinicaltrials.gov/ct2/show/NCT...
. A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants with Relapsing Multiple Sclerosis. (7 June 2021). Identifier: NCT04879628. Available online: https://clinicaltrials.gov/ct2/show/NCT...
biomarkers (B-type natriuretic peptide, hsCRP, cardiac troponin-I) prognostic value of sCD40L for ischemic events No association between sCD40L plasma levels and the risk for recurrent ischemic events in patients with non–ST-segment elevation ACS treated with GP IIb/IIIa receptor antagonist ...
A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol. Res. 7, 428–442 (2019). Nutt, S. L. & Chopin, M. Transcriptional networks driving dendritic cell differentiation and function. ...
The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood. 2008;112(3): 711-720... M Luqman,K Sha,K Lin,... - 《Blood》 被引量: 217发表: 2008年 Analysis of the promoter elements necessary for IL-4 and anti-CD40...
Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma Cancer Res, 65 (13) (2005), pp. 5898-5906 View in ScopusGoogle Scholar 24 SK Kelley, T Gelzleichter, D Xie, et al. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanize...